Vivani Medical Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: March 26, 2024 | Vivani Medical, Inc. |
|---|---|
| /s/ Adam Mendelsohn | |
| Adam Mendelsohn | |
| Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
The undersigned officers and directors of Vivani Medical, Inc., each hereby severally constitutes and appoints Adam Mendelsohn and Brigid Makes as their true and lawful attorney-in-fact and agent, with full power of substitution to sign and execute on behalf of the undersigned any and all amendments to this Annual Report on Form 10-K, and to perform any acts necessary in order to file the same, with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requested and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Adam Mendelsohn | Chief Executive Officer and Director | March 26, 2024 |
| Adam Mendelsohn | (Principal Executive Officer) | |
| /s/ Brigid Makes | Chief Financial Officer | March 26, 2024 |
| Brigid Makes | (Principal Financial and Accounting Officer) | |
| /s/ Gregg Williams | Chairman of the Board | March 26, 2024 |
| Gregg Williams | ||
| /s/ Aaron Mendelsohn | Director | March 26, 2024 |
| Aaron Mendelsohn | ||
| /s/ Dean Baker | Director | March 26, 2024 |
| Dean Baker | ||
| /s/ Alexandra Larson | Director | March 26, 2024 |
| Alexandra Larson | ||
| /s/ Daniel Bradbury | Director | March 26, 2024 |
| Daniel Bradbury | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID:207) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-7 |
| Notes to Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022 | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.